Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 05, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials".
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 05, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials".